Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE
NCT06134362Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- May 2024
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started May 2024; status: active, not recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06134362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134362.